EUVIMEDEUVIMED entdecken
Open Access

Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies

David H Quach iD, Premal Lulla iD, Cliona M Rooney iD

Blood · 2023

DOI: 10.1182/blood.2022016202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2023. Verfasst von David H Quach und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Virus Diseases. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptively transferred virus-specific T cells (VSTs) have shown remarkable safety and efficacy for the treatment of virus-associated diseases and malignancies in hematopoietic stem cell transplant (HSCT) recipients, for whom VSTs are derived from the HSCT donor. Autologous VSTs have also shown promise for the treatment of virus-driven malignancies outside the HSCT setting. In both cases, VSTs are manufactured as patient-specific products, and the time required for procurement, manufacture, and release testing precludes their use in acutely ill patients. Further, Good Manufacturing Practices–compliant products are expensive, and failures are common in virus-naive HSCT donors and patient-derived VSTs that are rendered anergic by immunosuppressive tumors. Hence, highly characterized, banked VSTs (B-VSTs) that can be used for multiple unrelated recipients are highly desirable. The major challenges facing B-VSTs result from the inevitable mismatches in the highly polymorphic and immunogenic human leukocyte antigens (HLA) that present internally processed antigens to the T-cell receptor, leading to the requirement for partial HLA matching between the B-VST and recipient. HLA mismatches lead to rapid rejection of allogeneic T-cell products and graft-versus-host disease induced by alloreactive T cells in the infusion product. Here, we summarize the clinical outcomes to date of trials of B-VSTs used for the treatment of viral infections and malignancies and their potential as a platform for chimeric antigen receptors targeting nonviral tumors. We will highlight the properties of VSTs that make them attractive off-the-shelf cell therapies, as well as the challenges that must be overcome before they can become mainstream.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationVirus DiseasesHumansT-LymphocytesCell- and Tissue-Based TherapyReceptors, Antigen, T-CellHLA Antigens

Substanzen

Receptors, Antigen, T-CellHLA Antigens

Autor:innen und Institutionen

  • Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX.
  • Department of Medicine, Baylor College of Medicine, Houston, TX.
  • Department of Pediatrics, Baylor College of Medicine, Houston, TX.
  • Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX.
  • Department of Molecular Virology and Immunology, Baylor College of Medicine, Houston, TX.

ORCID-Profile: David H Quach, Premal Lulla, Cliona M Rooney

Förderung

  • NCI NIH HHS
  • NIH HHS

Zitieren

APA

Quach, D. H., Lulla, P., & Rooney, C. M. (2023). Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies. Blood. https://doi.org/10.1182/blood.2022016202

Vancouver

Quach DH, Lulla P, Rooney CM. Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies. Blood. 2023. doi:10.1182/blood.2022016202

BibTeX
@article{Quach2023,
  author = {Quach, David H and Lulla, Premal and Rooney, Cliona M},
  title = {Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022016202}
}
Kostenlos starten →